# Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine

> **NCT01657526** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 48 (actual)

## Conditions studied

- Respiratory Disorders

## Interventions

- **BIOLOGICAL:** GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A)
- **BIOLOGICAL:** GSK Biologicals' Non-Typeable H. influenzae (GSK2838501A)
- **BIOLOGICAL:** Saline placebo

## Key facts

- **NCT ID:** NCT01657526
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-08
- **Primary completion:** 2013-11-25
- **Final completion:** 2013-11-25
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01657526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01657526, "Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01657526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*